Mario Mandalà

Associate Professor

University of Perugia
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab (NIVO) significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab (IPI) in patients with resected stage IIIB–C or stage IV melanoma, with benefit sustained at 4 years. We report updated 5-year efficacy and biomarker findings. Patients and Methods: Patients with resected stage IIIB–C/IV melanoma were stratified by stage and baseline PD-L1 expression and received NIVO 3 mg/kg every 2 weeks or IPI 10 mg/kg every 3 weeks for four doses and then every 12 weeks, both intravenously for 1 year until disease recurrence, unacceptable toxicity, or withdrawal of consent. The primary endpoint was RFS. Results: At a minimum follow-up of 62 months, RFS with NIVO remained superior to IPI (HR 0.72; 95% CI, 0.60–0.86; 5-year rates of 50% versus 39%). 5-year DMFS rates were 58% with NIVO versus 51% with IPI. Five-year OS rates were 76% with NIVO and 72% with IPI (75% data maturity: 228 of 302 planned events). Higher levels of TMB, tumor PD-L1, intratumoral CD8+ T cells and interferon-gamma–associated gene expression signature, and lower levels of peripheral serum C-reactive protein were associated with improved RFS and OS with both NIVO and IPI, albeit with limited clinically meaningful predictive value. Conclusion: NIVO is a proven adjuvant treatment for resected melanoma at high-risk of recurrence, with sustained, long-term improvement in RFS and DMFS compared with IPI and high OS rates. Identification of additional biomarkers are needed to better predict treatment outcome.

Year:

2024

Year:

2023

Collaborators (12)

Leslie A. Fecher

-

UNITED STATES
View details

vanna chiarion sileni

Chief of Melanoma Oncology Unit

-

ITALY
View details

James Larkin

Professor

-

UNITED KINGDOM
View details

Ana Arance

University of Barcelona

SPAIN
View details

Nikhil Khushalani

Assistant Center Director for Clinical Research Review and Partnerships; Senior Member and Vice-Chair, Department of Cutaneous Oncology

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Marcus Butler

University Health Network

CANADA
View details

Jean-Jacques Grob

Aix-Marseille University

FRANCE
View details

Helen Gogas

Head, Professor in Medical Oncology

National and Kapodistrian University of Athens

GREECE
View details

Paul Nathan

University College London

UNITED KINGDOM
View details

Ivan Marquez-Rodas

Universidad Complutense de Madrid

SPAIN
View details

Mark Middleton

University of Oxford

UNITED KINGDOM
View details

Paolo Antonio Ascierto

Full Professor

Università degli Studi di Napoli Federico II

ITALY
View details